COVID-19
4 years ago
The one time at #ACR20 that only one sceen is on! #LTF @FauciFan @RheumNow so much respect for Dr Fauci! https://t.co/jhvlc8Py7R
4 years ago
Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy.
Abs#0626 #ACR20 @RheumNow
https://t.co/E14y3e4ALi
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day one:
Safety of Recombinant Zoster Vaccine (RZV) (Abstract 0452…
Outcomes for Rheumatic Disease Patients with COVID-19: Dr Kathryn Dao
Dr. Kathryn Dao discusses plenary abstract #0430 presented Friday at the ACR 2020 annual meeting.
Dr. Janet Pope interviews A&R Editor Dr. Daniel Solomon
Dr. Janet Pope interviews Arthritis & Rheumatology Editor Dr. Daniel Solomon about his role as editor, COVID-19 related submissions, and overall journal submissions
4 years ago
Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB
4 years ago
#COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID pts. Glass is half empty. More hospitalization, ICU, ventilation but death 5% v 4.3%. Abstr#430 #ACR20 @RheumNow @CRASCRRheum https://t.co/cqko0Igd8L
4 years ago
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with rheum rx... they haven't read guidelines and may make their own changes! Prepare them for exposure/ifn! #ACR20 @Rheumnow 2F042 https://t.co/HkxbkYjEm3
Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum vs 688 nonrheum. No⬆️risk in rheums after adjusting for race/smoking/comorbidities for: hospitalizations, mech ventil'n 3. ICU 4. death #ACR20 Abstr#L01 @RheumNow https://t.co/362UZUe5dg